...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Additional Exempt Distribution

Additional Exempt Distribution

2023-09-26 (Alberta)

 

Promissory Note: $337,725.00 (CAN)

 

With 450,000 warrants @ $1.01, Expire 2023-09-26.

 

Koo

 

Share
New Message
Please login to post a reply